ACRO Biomedical, an expert in regenerative medicine, has been receiving good news recently. Following the publication of its important research result, “Supercritical carbon dioxide decellularized porcine cartilage graft with PRP attenuated OA progression and regenerated articular cartilage in ACLT-induced OA rats" in the Journal of Tissue Engineering and Regenerative Medicine, ACRO's latest product, ABCcolla^® Bone Matrix, has received US FDA 510(k) clearance. ABCcolla^® Bone Matrix is the new solution to bone defects caused by congenital defects or injuries.